RE: This is not 100% over yet!11 May 2026 15:34
Would it be easier for J & J to buy Trellus Health than wait to see if the management can find a solution to their immediate funding crisis?
(I know tere's nout we can do but wait but...)
Chat GPT answer:
Based on the financial situation of Trellus Health as of May 2026, an acquisition by Johnson & Johnson (J&J) would likely be more efficient than waiting for the company to resolve its funding issues, which are severe and nearing a potential break-up or insolvency.Why Acquisition May Be Easier/More Likely:Severe Funding Crisis: As of May 8, 2026, Trellus Health has suspended trading on the London Stock Exchange's AIM market, appointed restructuring advisers, and announced a cash runway that only extends into mid-June 2026.Direct "Sale" Option: The company is explicitly evaluating a "potential sale of its US subsidiary," which hosts the Trellus Elevate platform used by J&J.Extremely Low Valuation: Trellus Health's market capitalization has plummeted, with shares down 93% in the year leading up to April 2026, dropping to roughly £440,000. This makes it a very low-cost acquisition for a company the size of J&J.Immediate Platform Control: Acquiring the company would allow J&J to secure the intellectual property and development team, ensuring the, "continuing development" of the platform without risk of it being sold to a competitor or dissolving during bankruptcy.Why Waiting is Risky for J&J:Unstable Development: Trellus is currently cutting costs, reducing staff compensation, and renegotiating vendor contracts to survive. This environment is detrimental to long-term development of a digital platform.Uncertainty: Trellus has failed to secure long-term funding despite ongoing attempts and has previously had to rely on high-cost, dilutive convertible loans.High Risk of Disruption: If Trellus fails to find funding, it may be forced into insolvency, which could create legal and operational hurdles for J&J to reclaim or continue using the Trellus Elevate technology.Context of the Collaboration:J&J currently has a contract with Trellus (through mid-2026) for their IBD platform. The project has seen positive engagement metrics, which led to a, "broadening [of] patient access channels" in January 2026.Therefore, from a strategic standpoint, it is likely easier for J&J to simply acquire the troubled, low-value technology to guarantee its future development rather than waiting for a potentially disastrous resolution to Trellus's financial constraints.